Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in advanced NSCLC
NCT00124280Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2005
- Primary completion
- Oct 2007
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in non-small cell lung carcinoma (NSCLC), sponsored by Novartis. Primary endpoint: Objective Response Rate. Started Jul 2005; status: completed.
02
Drugs
everolimus
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00124280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124280.